Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.
FDA has issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, a RAS inhibitor.
